Hypothyroidism and obesity are associated with hyperlipidemia, non-alcoholic fatty liver disease (NAFLD) and atherosclerosis. Overt and subclinical hypothyroidism are commonly observed clinical disorders that exacerbate hyperlipidemia and hepatic lipid accumulation. Our laboratory has been investigating the mechanisms by which thyroid hormone (T3) regulates genes controlling hepatic metabolism. T3 can ameliorate hepatic steatosis in part by accelerating fatty acid oxidation and inhibiting lipogenesis. We identified several transcriptional coregulators that participate in T3 induction of lipid metabolizing genes including the peroxisome proliferator activated receptor gamma coactivator (PGC- 1?) and the deacetylase sirtuin 1 (SIRT1). Recently, we discovered that T3 inhibits the expression of several secretory phospholipases in the liver including secretory phospholipase group IIa (PLA2g2a). PLA2g2a has been linked with chronic inflammatory diseases including atherosclerosis and arthritis. Furthermore, PLA2g2a is elevated with hypothyroidism and diet induced obesity. The liver is one of the major contributors to the pool of extracellular PLA2g2a. Although PLA2g2a is highly expressed in hepatocytes, most previous studies have examined the regulation of PLA2g2a in macrophages and immune cells. We hypothesize that the T3 status modulates PLA2g2a expression and that the T3 mediated reduction in PLA2g2a is beneficial for hyperlipidemia.
In aim 1, we propose to define novel mechanisms by which T3 inhibits expression of PLA2g2a gene. We will focus on the recruitment of nuclear corepressors to the liganded TR on the PLA2g2a gene.
In aim 2, we will examine the role of PLA2g2a in hyperlipidemia and steatosis with hypothyroidism. Interest in the pharmacologic utility of T3 has been revitalized by the development of T3 receptor ? (TR?) selective agonists which act primarily in the liver to reduce plasma and hepatic lipids with little impact the cardiovascular system. Our studies will illuminate potential beneficial actions of T3 in the reduction of conditions associated with the metabolic syndrome such as hyperlipidemia and NAFLD. Obesity, steatosis and associated morbidities occur with very high frequency in the aging Veteran population.

Public Health Relevance

Hypothyroidism and obesity exacerbate the progression of hyperlipidemia, hepatic steatosis and cardiovascular disease. These conditions are very commonly observed in the aging Veteran population. The goal of our research is to identify potential therapeutic avenues for ameliorating the impact of hyperlipidemia. Recently developed thyroid hormone analogs have beneficial therapeutic actions in that they reduce steatosis and hyperlipidemia but do not elevate heart rate. We will determine the mechanisms by which thyroid hormone accelerates hepatic fatty acid oxidation, reduces lipid synthesis and diminishes the inflammation associated with fatty liver disease. Our investigations are highly relevant for the treatment of the hyperlipidemia and steatosis that are very prevalent in our Veterans.

Agency
National Institute of Health (NIH)
Institute
Veterans Affairs (VA)
Type
Non-HHS Research Projects (I01)
Project #
5I01BX002408-04
Application #
9551509
Study Section
Endocriniology A (ENDA)
Project Start
2015-07-01
Project End
2019-06-30
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Memphis VA Medical Center
Department
Type
DUNS #
078577285
City
Memphis
State
TN
Country
United States
Zip Code
38103
Dong, Qingming; Kuefner, Michael S; Deng, Xiong et al. (2018) Sex-specific differences in hepatic steatosis in obese spontaneously hypertensive (SHROB) rats. Biol Sex Differ 9:40
Distel, Emilie; Cadoudal, Thomas; Collinet, Martine et al. (2017) Early induction of pyruvate dehydrogenase kinase 4 by retinoic acids in adipocytes. Mol Nutr Food Res 61:
Gopal, Keshav; Saleme, Bruno; Al Batran, Rami et al. (2017) FoxO1 regulates myocardial glucose oxidation rates via transcriptional control of pyruvate dehydrogenase kinase 4 expression. Am J Physiol Heart Circ Physiol 313:H479-H490
Kuefner, Michael S; Pham, Kevin; Redd, Jeanna R et al. (2017) Secretory phospholipase A2 group IIA modulates insulin sensitivity and metabolism. J Lipid Res 58:1822-1833
Cook, George A; Lavrentyev, Eduard N; Pham, Kevin et al. (2017) Streptozotocin diabetes increases mRNA expression of ketogenic enzymes in the rat heart. Biochim Biophys Acta Gen Subj 1861:307-312
Li, Jing Jing; Wang, Ruishan; Lama, Rati et al. (2016) Ubiquitin Ligase NEDD4 Regulates PPAR? Stability and Adipocyte Differentiation in 3T3-L1 Cells. Sci Rep 6:38550
Deng, Xiong; Dong, Qingming; Bridges, Dave et al. (2015) Docosahexaenoic acid inhibits proteolytic processing of sterol regulatory element-binding protein-1c (SREBP-1c) via activation of AMP-activated kinase. Biochim Biophys Acta 1851:1521-9
Dong, Qingming; Giorgianni, Francesco; Beranova-Giorgianni, Sarka et al. (2015) Glycogen synthase kinase-3-mediated phosphorylation of serine 73 targets sterol response element binding protein-1c (SREBP-1c) for proteasomal degradation. Biosci Rep 36:e00284